Fully humanized monoclonal antibody to VEGF
Type of medical product:
Phase II-III clinical studies
Apagin® is a fully humanized monoclonal antibody, targeting vascular endothelial growth factor (VEGF). A malignant tumour needs blood supply for its growth; therefore cancer cells secrete vascular growth factor (VEGF), which binds to its receptor promoting the growth of blood vessels in the tumour. It is known that the blocking of the VEGF signaling inhibits tumour growth. Similar antibody Avastin®, developed by Genentech has been used for treatment of various types of cancer for several years, but it has serious side effects.
During preclinical studies Apagin® has demonstrated a good selectivity in blocking the interaction between VEGF with type II VEGF-receptors without affecting the interaction with the VEGF type I receptors (unlike Avastin®), which could possibly improve its safety profile..
This produc is intended for use for several oncological indications: colorectal cancer, non-small cell lung cancer, breast cancer, glioblastoma and ophthalmic conditions. Currently, this medication is undergoing clinical trials.
The development of this biosimilar is carried out in collaboration with Affitech AS, Norway — one of the World leaders in the development of fully humanized monoclonal antibodies for a wide range of the therapeutic targets: from relatively easy to the most complex ones. To meet these ambitious objectives our company has developed the specialized technology platforms MBAS™ and CBAS™.
- In our in vivo studies Apagin® has shown the efficacy, which is similar or superior to that of Avastin® in a range of mouse xenograft models.
- has shown high efficiency in combination with chemotherapy in mouse xenograft models of colorectal cancer.
- has demonstrated a superior safety profile in rodents and primats.
The sponsor of this research program is the Ministry of Industry and Trade of the Russian Federation.